Vestcor Inc Acquires 3,291 Shares of DexCom, Inc. (NASDAQ:DXCM)

Vestcor Inc boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 26.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,832 shares of the medical device company’s stock after purchasing an additional 3,291 shares during the quarter. Vestcor Inc’s holdings in DexCom were worth $1,231,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the business. Versant Capital Management Inc purchased a new position in shares of DexCom in the 4th quarter worth approximately $25,000. Private Trust Co. NA lifted its position in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after buying an additional 245 shares during the last quarter. Larson Financial Group LLC boosted its stake in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after buying an additional 137 shares during the period. Heck Capital Advisors LLC bought a new position in DexCom during the fourth quarter valued at $38,000. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of DexCom in the fourth quarter valued at $49,000. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 104,657 shares of company stock worth $8,019,422 over the last quarter. Insiders own 0.30% of the company’s stock.

DexCom Price Performance

NASDAQ DXCM opened at $70.69 on Friday. The company has a market cap of $27.62 billion, a PE ratio of 49.43, a P/E/G ratio of 2.30 and a beta of 1.28. The firm’s 50 day moving average price is $83.99 and its 200-day moving average price is $76.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on DXCM shares. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and boosted their target price for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Canaccord Genuity Group boosted their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Finally, Morgan Stanley increased their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.